24/7 Wall Street
25 Feb 2026, 18:33 UTC · 35w ago
Verdict
Headline leans bullish. We score IOVA +1.00 across five claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+1.00strongly bullish
What the story claims
5 claims · scored −1 bearish … +1 bullish
Iovance Biotherapeutics received FDA Fast Track designation for NSCLC, targeting a market seven times larger than melanoma.
More positive than 99% of claims this week
The company internalized manufacturing at its Philadelphia facility, supporting 5,000 patients annually with a 32-day turnaround.
So whatInternalized production creates a competitive moat and structural cost advantages that improve margins.
Continue reading
5 related stories
More positive than 99% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 92% of claims this week
Q4 revenue reached $86.71 million (up 17.7% YoY) with gross margins expanding to 50% from 38.2%.
More positive than 85% of claims this week
The company expects 'remarkable revenue growth in 2026' with formal guidance forthcoming.
More positive than 76% of claims this week
NSCLC trial enrollment completion and the soft tissue sarcoma Phase 2 launch are scheduled for Q2 2026.
More positive than 62% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
Strong Q4 revenue growth, expanding gross margins, and positive analyst sentiment.
More positive than 88% of ticker scores this week
Shares surged 35.4% alongside a shift in positive retail investor sentiment.
More negative than 86% of ticker scores this week
Shares fell significantly and the stock has pulled back sharply.
More positive than 75% of ticker scores this week
Posted Q1 2026 results that beat revenue expectations.
More positive than 75% of ticker scores this week
Posted Q1 2026 results that beat revenue expectations.
More negative than 78% of ticker scores this week
Mentioned as having pulled back sharply.
More negative than 78% of ticker scores this week
Mentioned as having pulled back sharply.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
46m ago
+128.0%
Price agrees with the score
$8.62 vs $3.78 close before publication (Feb 24) · not market-adjusted
IOVA chart →
